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No. S220250 
IN THE SUPREME COURT 
OF THE STATE OF CALIFORNIA 
PDX, INC. & NATIONAL HEALTH INFORMATION 
NETWORK, INC., 
Defendants and Appellants, 
vs. 
KATHLEEN HARDIN and DANE HARDIN, 
PlaintiffS and Respondents. 
REAL PARTIES IN INTEREST'S 
ANSWER TO DEFENDANTS/APPELLANTS PDX, INC. & 
NATIONAL HEALTH INFORMATION NETWORK, INC.'S 
PETITION FOR REVIEW 
INTRODUCTION: WHY REVIEW SHOULD BE DENIED 
Petitioners PDX, Inc. and National Health Infonnation Network, Inc. 
(collectively "PDX") ignore the record and the Court of Appeal's statement 
of the issues and facts in contending that the decision burdens First 
Amendment speech. That is not the case. The Court of Appeal decision 
does not allow for liability for truthful statements in public records. This 
case involves PDX's conduct, the intentional modification of its software 
so that Safeway could distribute patient drug education monographs that 
excluded warnings, conduct that PDX knew would pose a risk ofhann to 
consumers. 
Nonetheless, PDX seeks review contending that the Court of Appeal 
decision is unprecedented and inconsistent with First Amendment 
principles. PDX's First Amendment arguments are premised on the factual 
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misstatement that the monograph was a truthful statement based on public 
records. There is no dispute that the monograph given to Mrs. Hardin 
omitted FDA-mandated black box warnings about life threatening risks of 
taking Lamotrigine. 
In its decision under the anti-SLAPP statute, the Court of Appeal did 
not decide whether PDX' s conduct was in furtherance of the exercise ofthe 
constitutional right of petition or free speech. 
The Court of Appeal's decision rests on the second prong of the anti-
SLAPP statute, whether plaintiffs showed a probability of prevailing on the 
merits. PDX never attempted to defend the reasonableness of its conduct in 
the court below. Its primary argument in the Court of Appeal was that it 
owed no duty to ]Vtts. Hardin as a matter oflaw. In rejecting these 
contentions, the Court of Appeal applied the law of negligence in line with 
established prccedent. The Court of Appeal conducted an independent 
review of the record to determine under the anti-SLAPP statute that the 
evidence presented was sufficient to support a favorable judgment. As 
such, Plaintiffs' negligence and products liability claims withstood PDX's 
anti-SLAPP motion. 
PDX further contends that the Court of Appeal erred when it found 
PDX assumed a duty of care and contends that the opinion is, therefore, in 
conflict with Rivera v. First Databank, Inc. (2010) 187 Cal.App.4th 709, on 
which PDX relied for the contention that it owed no duty to Mrs. Hardin as 
a matter oflaw. PDX's assertions fail on several grounds. First, PDX 
essentially seeks review for determinations as to controlling factual issues 
that may not be decided at the pleading stage. As noted by the Court of 
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Appeal, factual issues such as those raised by PDX go to whether PDX 
acted with due care, and are not relevant to finding whether PDX assumed a 
duty under California law. Second, PDX ignores the distinctions made by 
the Court of Appeal between this case and Rivera, distinctions that were 
based on evidence in this case. The Court of Appeal explained that, unlike 
in Rivera, there was in this case an FDA-required black box warning that 
applied to all consumers, and it was omitted. PDX knew - and even told 
Safeway - that warnings were required to avoid injury to consumers. 
Nonetheless, PDX entered into a contract with Safeway in 2006 to modifY 
its software so that abbreviated monographs without important warnings 
would be given to Safeway customers. Review of these controlling factual 
determinations at this stage would be premature. An anti-SLAPP motion is 
decided at the pleading stage prior to discovery, not after full discovery, as 
with a motion for summary judgment. 
PDX petitions for review on the additional grounds that it is 
insulated from liability pursuant to Section 230 of the Communications 
Decency Act This argument does not warrant review because the Court of 
Appeal found, based on relevant law and the evidence in this case, that 
Section 230 does not immunize PDX. The Court of Appeal correctly 
found, based on the evidence, that Plaintiffs' claims do not arise from 
PDX's role as a distributer of information that was furnished by another 
content provider. 
Finally, there is no concern that courts in the future would 
interpret this decision as allowing liability for truthful statements about 
public records because the Court of Appeal's decision hinges on the 
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evidence in this case and makes narrow findings. Review would be 
unnecessary and premature. 
STATEMENT OF THE CASEI 
A. PDX provided software that assembles and prints patient 
educatio_n monographs. 
PDX is "'an independent provider of software that distributes drug 
infonnation to phannacy customers'" including patient drug edncation 
monographs ("monographs"). (Op. at 2.) The monographs are authored by 
third parties, in this case Wolters Kluwer Health, Inc. ("WKH"), an 
independent publisher of patient education drug monographs and are 
summaries of infonnation from package inserts and medication guides 
"written in lay language for consumers" to supplement oral counseling 
received when a prescription is filled. (Op. at 2 & 3 [referencing generally 
Rivera v. First Databank, Inc. (2010) 187 Cal.App.4th 709,713 (Rivera)].) 
Based on the record, the Court of Appeal found that there was no factual 
dispute as to the nature ofPDX's activity. (Op. at 2.) 
PDX has a licensing agreement with WKH to obtain and provide the 
infonnation in monographs through its software, enabling phannacies to 
print and distribute monographs when a prescription is filled. (Op. at 3.) 
According to PDX, the purpose ofthe monograph is to provide patients 
useful, accurate and comprehensive infonnation about thcir prescription 
I Real parties in interest agree with the facts stated in the Court of 
Appeal's opinion. We summarize those facts and supplement with 
additional facts from the record. 
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drug, including waruings of known health risks associated with the drug. (3 
C.T. 719 [Loy Decl. 'll9].) 
PDX had a license agreement with Safeway, Inc. ("Safeway") to 
provide its software for use by Safeway in its pharmacies. (3 C.T. 717; Op. 
at 2-3.) Under this agreement, Safeway paid PDX in excess of$l million 
every year in license and maintenance fees for 605 Safeway pharmacies in 
the U.S. and Canada. (3 C.T. 725-737.) Using the PDX software, Safeway 
automatically prints monographs, which are attached to a label with the 
patient's personal information. (3 C.T. 688 [Safeway Person Most 
Knowledgeable Depo. ("PMK Depo") 26: 13-23][ emphasis added].) 
Safeway considers the monograph to be part of the label. (3 C.T. 686 [PMK 
Depo.20:11-21].) 
B. The Industry staved off mandatory FDA regUlation of patient 
drug information by adopting an industry "Action Plan." 
In 1996, Congress enacted Public Law 104-180, which was an 
industry-supported alternative to the FDA's proposed regulations that 
would have required a regulatory approval process for drug infonnation 
sheets or monographs. (3 C.T. 776; Op. at 2.) 
P.L. 104-180 required that "health care professionals, consumer 
organizations, voluntary health agencies, the pharmaceutical industry, drug 
wholesalers, [and] patient drug information database companies" develop a 
plan: 
to ensure the transmittal of useful information 
to the consuming public, including being 
scientifically accurate, non-promotional in tone 
and content, sufficiently specific and 
comprehensive as to adequately inform 
consumers about the use of the product, and in 
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an understandable, legible format that is readily 
comprehensible and not confusing to consumers 
expected to use the product. (3 C.T. 770. 110 
Stat. 1593 [Aug. 6.1996].) 
Under P.L. 104-180, the FDA could not enact mandatory regulations 
of consumer drug information ifthe industry came up with its own "Action 
Plan" to address the problem of inadequate drug information to consumers. 
(3 C.T. 776.) 
In 1996, drug product information producers (including WKH), 
pharmacists, physicians, phannaceuticalcompanies, industry associations 
and consumer advocates collaborated on a "private sector initiative aimed 
at preventing further FDA regulation" by ensuring that the companies met 
the goals ofP.L. 104-180. (3 C.T. 741, 813-819; SAA 055.) The industry 
committee issued its "Action Plan for the Provision of Useful Prescription 
Medicine Information" ("Action Plan" or "Keystone Criteria") in 
December 1996. (3 CT 767-822.) The Secretary of Health and Human 
Services approved the Action Plan in January 1997. (3 C.T. 762; Op. at 2.) 
"The goals [ofthe Keystone Criteria] were to improve the quality of 
information, and thereby reduce injury." (3 C.T. 719 [Loy Dec!. 
~ 9][emphasis added].) '''The purpose of this Action Plan is to improve the 
quality and availability of useful information that is voluntarily provided to 
consumers with their prescription medicines. The rationale for the Plan is 
that providing consumers with useful information about their prescription 
medicines can reduce the risk of preventable, medication-induced injury 
and improve health outcomes.'" (Op. at 2 [quoting the Action Plan].) The 
Action Plan defined useful information as "'that which is sufficiently 
comprehensive and communicated such that consumers can make informed 
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decisions about how to receive the most benefit from medicines and protect 
themselves from harm. Both the substance and presentation of the 
information are important. '" (ld.) 
Prior to 2005, PDX software permitted retailers, including Safeway, 
to print abbreviated (five-section) or complete (eight-section) versions of 
the drug monograph for a given drug. (Op. at 3.) The five-section 
monographs excluded three sections: "Before Using This Medicine", 
"Overdose" and "Additional Information." (3 C.T. 718 [Loy Dec!. '1[7]; Op. 
at 3.) The excluded section "Before Using This Medicine" contained 
warnings as to known serious risks from the prescription drug. (ld.) 
In 2005, PDX revised its software program to prevent retailers, 
including Safeway, from printing abbreviated drug monographs. (3 C.T. 
719 [Loy Dec!. ,r 12]; Op. at 3.) Benjamin Loy, Senior Vice President of 
Industry Relations for PDX, Inc. and National Health Information Network, 
Inc. stated that '''[t]his software revision was made in response to both 
regulatory guidelines for the provision of patient education information and 
an internal recommendation by Jim Boyd, R.Ph., then Sr. Vice President 
[ofJ Network Services NHlN. '" (Op. at 4-5 [quoting the trial court's 
ruling].) 
C. PDX intentionally modified its software to permit Safeway to 
provide abbreviated monographs. 
In 2006, after PDX made printing all eight-sections mandatory, "'a 
Safeway representative contacted PDX because it wanted to use the five 
section monograph, rather than the eight section monograph with the 
warnings at issue here.'" (ld.) Thus, in 2006, PDX and Safeway entered 
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into a written agreement in which PDX agreed to provide '''[p]rogramming 
to allow the system to provide the five section monograph ... '" after PDX 
"obtained a release ofliability and indemnity from Safeway." (Op. at 3 & 5 
[emphasis added].) 
In the 2006 agreement with Safeway, PDX acknowledged "that 
providing the full eight-section version would better enable patients to 'use 
the medication properly and appropriately, receive the maximum benefit, 
and avoid harm. '" (Op. at 11 [quoting the 2006 agreement with Safeway] 
[emphasis added].) 
D. Kathleen Hardin was given a five-section monograph that 
omitted necessary warnings. 
Plaintiff Kathleen Hardin suffered complete blindness, as well as 
pennanent, severe and painful scarring as a result of Stevens-Johnson 
Syndrome ("SIS") and Toxic Epidennal Necrolysis ("TEN") caused by 
taking Lamotrigine, the generic form ofLamicta1.2 (Op. at 1.) Plaintiff 
later leamed that Lamotrigine carries a significant risk of SIS and TEN. 
(Op. at 1.) 
Since 1994, the FDA has required "boxed warnings" about the 
possibility of "life threatening rashes" caused by Lamictal. (1 C.T. 40 [Loy 
Dec!. ~ 11].) Also called "black box warnings," this is the strongest 
waming that the FDA requires and signifies that medical studies indicate 
2 Lamotrigine is the generic form ofLamicta!. The names are used 
interchangeably throughout this answer. 
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that the drug carries a significant risk of serious or even life-threatening 
adverse effects. (21 C.F.R. § 201.57 (c)(1).) 
Mrs. Hardin filled her prescription for Lamictal at a Safeway 
pharmacy. (Op. at 3.) The abbreviated monograph was the only product 
information she received with her prescription and was the only 
infonnation she read and considered in deciding to take Lamictal. (Op. at 
3.) The monograph was attached to a label with her personal information. 
(3 C.T. 664, 667.) 
The abbreviated monograph provided to Mrs. Hardin excluded the 
"Black Box" warnings that were contained in the section "Before Using 
This Medicine," which was one of the sections omitted from the five-
section Lamotrigine monograph that WKr-r provided to PDX. The omitted 
warning stated: 
WARNING: SERIOUS AND SOMETIMES FATAL 
RASHES HA VB OCCURRED RARELY WITH THE 
USE OF THIS MEDICINE .... Contact your doctor 
immediately if you develop rash symptoms, including 
red, swollen, blistered, or peeling skin. Treatment with 
this medicine should be stopped unless it is clearly 
determined that the medicine did not cause the rash. 
Even ifthe medicine is stopped, a rash caused by this 
medicine may still become life threatening or cause 
serious side effects (such as pennanent scarring.) (Op. 
at 3-4.) 
If Mrs. Hardin had been given the warning of serious and sometimes 
fatal rashes, she would have read it and would not have taken the 
medication. (Op. at 4.) 
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E. The trial court denied PDX's anti-SLAPP motion to strike. 
Kathleen Hardin and her husband sued her physician, the generic 
drug company that manufactured and distributed Lamotrigine, Safeway, 
Inc., WKH and Doe Defendants. (Op. at 1-2.) WKH filed a motion to 
strike Mrs. Hardin's claims under Code of Civil Procedure section 425.16 
(the "anti-SLAPP" statute). (Op. at 4.) WKH asserted that Plaintiffs' 
negligence and products liability claims against it arose from WKH's 
"protected speech concerning a public issue or an issue of public interest." 
(Op. at 1 & 4.) Attached to WKH's motion was a complete eight-section 
Lamotrigine monograph that included the section titled "Before Using This 
Medicine." (3 C.T. 674-678.) The trial court granted WKI-['s motion to 
strike and ruled that "WKH's production of drug monographs was 
protected speech under section 425.16, subdivision (e)(4)." As to the 
second prong, the trial court ruled that Plaintiffs "had no probability of 
prevailing on her claims because, following the rationale of Rivera, supra, 
187 Cal.App.4th 709, she could not establish that WKH owed her any 
duty." (Op. at 4.) 
Plaintiffs amended their complaint to allege causes of action for 
negligence and products liability against PDX. (Op. at 4.) PDX filed an 
anti-SLAPP motion to strike and argued that the claims against it were 
identical to those brought against WKH and should be dismissed for the 
same reasons. (Op. at 4.) "The trial court disagreed" and found that the 
"activity underlying PDX's alleged liability was the reprogramming of its 
software to permit Safeway to give customers an abbreviated, five-section 
monograph that omitted warnings about SJS instead of the full eight-section 
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version that included those warnings." (Op. at 4.) The trial court 
concluded: "'Plaintiffs have asserted acts by PDX that go beyond mere 
distribution of the WKH's monographs'" and "that PDX's reprogramming 
activities were not acts in furtherance of the defendant's right of petition or 
free speech within the meaning of section 425.16 and denied PDX's motion 
to strike." (Op. at 4 & 5.) PDX appealed the trial court's ruling. 
F. The Court of Appeal affirmed the trial court's ruling denying 
PDX's Anti-Slapp Motion to Strike. 
The Court of Appeal in a unanimous decision affIrmed the trial 
court's ruling, finding that the trial court had not erred in denying PDX's 
anti-SLAPP motion to strike "because the plaintiff demonstrated a 
probability she may prevail on her claim." (Op. at 1.) 
The Court of Appeal noted that the trial court had denied the anti-
SLAPP motion on the first prong, ruling that "PDX's role in the production 
and dissemination ofthe short-fonn monograph Hardin received was not 
'conduct in furtherance of the exercise of the constitutional right of petition 
or the constitutional right of free speech ... '" (Op. at 7.) The Court of 
Appeal detennined that it "need not answer this interesting question, for, 
assuming arguendo that Hardin's claims against PDX arose from protected 
first amendment activity, if credited at trial her evidence would be 
sufficient to support afavorablejudgment." (Op. at 7 [emphasis added].) 
Thus, the Court of Appeal reviewed the "trial court's detenninations as to 
whether the plaintiff has shown a probability of prevailing independently." 
(Op. at 6-7 [citing ComputerXpress, Inc. v. Jackson (2001) 93 Cal. App. 4th 
993,999] [emphasis added].) 
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As noted by the Court of Appeal, in order to prevail on an anti-
SLAPP motion, a plaintiff need only provide '''evidence establishing a 
prima facie case which, if believed by the trier of fact, will result in a 
judgment for the plaintiff" and that the Court "'accept as true the evidence 
favorable to the plaintiff [citation] and evaluate the defendant's evidence 
only to determine if it has defeated that submitted by the plaintiff as a 
matter oflaw. '" (Op. at 7 [quoting Nygard, Inc. v. Uusi-Kertyla (2008) 159 
Cal.App.4th 1027, 1036].) The Court of Appeal further noted that the 
"burden placed on the plaintiff must be compatible with the early stage at 
which the motion is brought and heard [ citation] and the limited 
opportunity to conduct discovery." (Id. [quoting Wilcox v. Superior Court 
(1994) 27 Cal.App.4th 809,823].) "[O]nly a minimal showing of merit is 
required." (Id. [quoting Yu v. Signet Bank/Virginia (2002) 103 Cal.App.4th 
298,318].) 
The Court of Appeal held that the record in this case "sufficiently 
makes out a claim that PDX assumed a duty of care by undertaking to 
render services to Safeway 'of a kind [it] should have recognized as 
necessary for the protection of third persons ... " (Op. at 11.) 
The Court of Appeal in so finding determined that Rivera did not 
control for several reasons. (Op. at 8.) First, the "evidentiary shortcomings 
presented in Rivera are not present here." (Op. at 8-9.) In Rivera, plaintiff 
provided no evidence to support the allegation that the monograph excluded 
a black box warning, or that the black box warning would have applied to 
the plaintiff in that case. In this case, the evidence shows that a black box 
warning existed, that it was intentionally excluded from the monograph 
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Plaintiff received and that it would have applied to all consumers of the 
drug. (Id.) 
Second, Rivera did not consider, as alleged in this case, the negligent 
undertaking doctrine. The Court of Appeal cited section 324A of the 
Restatement (Second) of Torts, which provides, in part: '''One who 
undertakes ... to render services to another for which he should recognize 
as necessary for the protection of a third person of his things, is subject to 
liability to the third person for physical hann resulting from his failure to 
exercise reasonable care to [perform] his undertaking ... '" (Op. at 9.) The 
Court set forth the requirements under section 324A and cases applying 
section 324A, inciudingArtiglio v. Corning, Inc. (1998) 18 Ca1.4th 604. 
(Op. at 10.) The Court then held that "PDX knew that enabling Safeway to 
print the abbreviated monograph could place patients at risk ... " (Op. at 
10.) The evidence in support of this included, among other things, the 2006 
agreement between Safeway and PDX that specifically noted that the 
complete eight-section monograph would "better enable patients to 'use the 
medication properly and appropriately, receive the maximum benefit, and 
avoid hann. '" (Op. at 11.) Based on this record, the Court of Appeal found 
that PDX had assumed a duty of care. (Op. at II.) 
Third, the Court of Appeal rejected the contention that PDX had no 
duty on the grounds that the monograph L'1dicated "it did not cover all 
possible adverse effects aod advised patients to read the medication guide . 
. . " (Op. at 11.) This disciaimerwas irrelevant to the scope ofPDX's duty. 
(Id.) Instead, the Court of Appeal noted: 
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The cited provisos and their foreseeable effect on 
consumers are relevant to whether PDX acted with due 
care when it enabled Safeway to omit warnings from 
WKH monographs, but it is the nature ofPDX's 
undertaking, not the care with which it was carried ont, 
that determines whether it assnmed a duty nnder 
section 324A in the first place. 
(Op. at 1l.) 
The Court of Appeal similarly rejected each ofPDX's 
remaining arguments. The court rebutted the contention that section 230 of 
the federal Communications Decency Act (47 U.S.C. § 230)("CDA) 
"immunizes [PDX] from liability for providing electronic access" to 
monographs. The Court of Appeal clarified that the claims do not arise 
from PDX's role as a service provider enabling Safeway to access software. 
(Op. at 12.) Instead, "Hardin sued PDX because it intentionally modified 
its software to allow Safeway to distribute abbreviated drug monographs 
that automatically omitted warnings of serious risks" and, as such, the 
Court of Appeal affirmed that "'this is not a case in which a defendant 
merely distributed information from a third party author or publisher. "" 
(Op. at 12 [emphasis added].) 
The Court of Appeal further addressed PDX's claims that the 
First Amendment and Civil Code section 4 7( d) "immunize it from liability 
for distributing what it describes as 'truthful summaries of the FDA's 
Package Insert and Medication Guide.'" (Op. at 13.) The Court of Appeal 
stated that "[i]t has not been established at this juncture that WKH's 
monographs are 'truthful summaries' of official FDA proceedings" or that 
"they qualifY as 'public journals''', or "that they 'do nothing to dilute' the 
warnings in FDA-approved medication guides ... and are not otherwise 
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misleading." (Op. at 13.) There is no evidence that monographs are not 
misleading. PDX's evidence did not defeat evidence "submitted by Hardin 
as a matter oflaw." (Op. at 13.) 
PDX petitioned the Court of Appeal for rehearing on the 
grounds that the Court of Appeal's opinion "did not resolve Plaintiffs' 
products liability claim" and "misstated -and/or omitted a number of 
material facts", including, according to PDX, the fact that the Action Plan 
provides guidelines and does not carry the force of the law. (Pet. Reh., filed 
7/7/14, 1.) PDX presented arguments similar to the arguments presented in 
its petition for review. The petition for rehearing was denied. The Court of 
Appeal held that "Hardin's theory is that PDX's software program, not the 
information it produces, is the defective product. PDX has not argued, let 
alone shown, that Hardin cannot prevail under that theory. Maybe so, but 
at this early juncture we carmot so conclude." (Order, 7/21114.) The Court 
of Appeal reaffirmed that "'[tJhe causes of action need only be shown to 
have 'minimal merit.'" (Order, 7/21114.) 
LEGAL DISCUSSION 
I. REVIEW IS NOT NECESSARY BECAUSE THE PETITION 
FAILS TO PRESENT A FIRST AMENDMENT ISSUE BASED 
ON THE RECORD IN THIS CASE. 
PDX's First Amendment arguments are premised on the c1aim-
repeated throughout the petition - that the monograph was a "truthful 
statement ... based on public records." (Pet. at 18.) That is a material 
factual misstatement. As stated in the Court of Appeal, there is no dispute 
that the monograph omitted the black box warning, the most important of 
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all the warnings, as to "serious and sometimes fatal rashes." (Op. at 12.) 
The logic ofPDX's arguments would permit an immunity for 
misrepresentations. 
Even further, in so arguing, PDX sets forth factual contentions, 
based on the language of the monograph, and asks that this Court review 
this case and the language of the monograph to make a determination as to 
controlling facts as a matter of law. (Op. at 19.) Such review is 
unnecessary and premature. The Court of Appeal stated that PDX's 
evidence has not defeated that submitted by Plaintiffs as a matter of law. 
(Op. at 13.) Factual issues must be developed in the trial court beyond the 
pleading stage. 
As to PDX's new argument that the First Amendment requires 
"knowing falsity" for liability, PDX did not make that argument in the 
Court of Appeal. (Pet. at 24.) The Supreme Court does not ordinarily 
"consider an issue that the petition failed to timely raise in the comi of 
appeal." (Cal. Rules of Court, rule 8.5000(c)(l).) In any cvent, the record 
here was sufficient to establish knowing falsity because PDX "intentionally 
modified its software to allow Safeway to distribute abbreviated drug 
monographs" that excluded warnings that it knew were important to avoid 
harm to consumers. (Op. at 11 & 12.) 
While PDX's petition attempts to reframe the Comi of Appeal's 
decision as premising liability on truthful statements, as the trial court 
observed, PDX's conduct went "'beyond mere distribution of the WKH's 
monographs'" and "that PDX's reprogramming activities were not acts in 
furtherance of the defendant's right of petition or free speech within the 
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meaning of section 425.16 ... " (Op. at 4 & 5.) The Court of Appeal did not 
decide this issue. The Court of Appeal's decision rests on the second prong 
of the anti-SLAPP statute and was an independent basis for affirming the 
trial court ruling. To the extent that PDX may be asking this Court to 
decide whether its conduct was somehow protected activity for the 
purposes of the first prong of the anti-SLAPP statute, that issue is moot. 
The Court of Appeal explicitly stated that it reviewed the 
"probability of prevailing independently" and decided that it did not have to 
answer the question raised by the first prong as the trial court did before it, 
because it stated that, even "assuming arguendo that Hardin's claims 
against PDX arose from protected first amendment activity, if credited at 
trial her evidence would be sufficient to support afavorable judgment." 
(Op. at 7 [emphasis added].) While PDX now argues that this case presents 
the First Amendment issue of liability for "truthful statements" ~ without 
ever mentioning the anti-SLAPP statute ~ PDX ignores the evidence in the 
case to the contrary and thatthe case arises out of its conduct. 
II. REVIEW SHOULD NOT BE GRANTED BECAUSE THE 
FACTUAL RECORD IS INCOMPLETE AND THERE IS NO 
CONFLICT OF LAW TO RESOL YE. 
The Court of Appeal affirmed the denial ofPDX's anti-SLAPP 
motion, which means the case returns to the trial court for discovery and 
trial. Review of controlling factual issues at this time would be premature. 
The Court of Appeal noted that "'the burden placed on the plaintiff must be 
compatible with the early stage at which the motion is brought and heard 
[citation] and the limited opportunity to conduct discovery. ", (Op. at 7 
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[quoting Wilcox v. Superior Court (1994) 27 Cal.App.4th 809, 823, 
disapproved on other ground in Equilon, supra, 29 Cal.4th at p. 68, fu. 5].) 
Controlling factual issues must be developed at the trial court. Plaintiffs 
met their burden at this stage. The standard required in evaluating the 
causes of action, as well as the evidence in support thereof in the context of 
the two-step process delineated in the anti-SLAPP statute is clearly set forth 
in the Court of Appeal's decision. (Op. at 7.) 
Nonetheless, PDX is requesting that detenninations be made as to 
controlling facts at the pleading stage and prior to discovery. As to the 
existence of a duty PDX owed to Plaintiff, PDX again bases its argument 
on the same misstatement - that the monograph PDX produced is "truthful 
consumer product infonnation." (Pet. at 26.) The Court of Appeal 
addressed this point as stated hereinabove. PDX argues that there could be 
no liability under a negligent undertaking theory because Mrs. Hardin's 
injuries were not foreseeable. (Pet. at 36.) This argument flies in the face 
ofthe evidence and the law as articulated by the Court of Appeal, including 
the contract that PDX and Safeway entered into (contained in the record), in 
which PDX expressly acknowledged that the complete monograph (which 
included the black box warning) were necessary to comply with industry 
standards and to "avoid harm" to consumers. (3 C.T. 762.) 
PDX contends that certain facts, including that Safeway decided to 
givc a five-section monograph, that the FDA re.quired a medication guide, 
that PDX relied on others to provide warnings (for which there is no 
evidence), and that the monograph referred to a medication guide (an 
argument the Court of Appeal explicitly addressed in its opinion), warrant 
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review by the Supreme Court as to PDX's liability under a theory of 
negligent undertaking. (pet. at 7; Op. at 8.) However, PDX's arguments do 
not make review necessary because the arguments are factual arguments 
that go to whether or not PDX acted with due care or caused the injuries, 
and do not show that the Court of Appeal's finding of whether it assumed a 
duty under section 324A, was erroneous under the applicable law. (Op. at 
11.) PDX seeks review to have its defenses prematurely evaluated and to 
thereby make an anti-SLAPP motion, a motion at the pleadings stage which 
precludes discovery, into a motion for summary judgment. 
The Court of Appeal further properly addressed arguments ofthis 
nature when it noted that it "disagreed with PDX's view that, as a matter of 
law, this language had any bearing upon the scope of [PDX's] duty." (Op. 
at 11.) Instead, the Court of Appeal determined that "the cited provisos and 
their foreseeable effect on consumers are relevant to whether PDX acted 
with due care when it enabled Safeway to omit warnings from WKH 
monographs, but it is the nature of P DX's undertaking, not the care with 
which it was carried out, that determines whether it assumed a duty under 
section 324A in the first place." (Op. at 11 [emphasis added].) 
PDX further asserts that under Rivera, it had no duty. Rivera is not 
persuasive authority in that it does not cite authority for, nor stand for the 
proposition that, the producer of consumer drug information owes no duty 
to consumers. Ba&ed on the Court of Appeal's decision, there is no conflict 
oflaw as PDX suggests. (pet. at 8.) As the Court of Appeal explained, 
Rivera is not controlling because "[ u ]nlike Rivera, here there was evidence 
that the black-box waming had been deleted from the monograph Hardin 
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received with her prescription" and that it "would have applied to all 
potential consumers ofLamotrigine." (Op. at 8-9.) 
Finally, PDX's petition regarding the products liability theory is also 
premature for the same reasons as stated above. Again, the Court of 
Appeal in its opinion affirmed the denial of an anti-SLAPP motion to 
strike, which means the case returns to the trial court for discovery and 
trial. As the Court of Appeal stated, "at this early juncture we cannot 
... conclude" that PDX has shown that it must prevail on the products 
liability claim as a matter oflaw. (Op. at 20.) 
m. REVIEW IS NOT NECESSARY BECAUSE THE COURT OF 
APPEAL CORRECTLY APPLIED SECTION 230 OF THE 
COMMUNICATIONS DECENCY ACT TO THE INSTANT 
CASE. 
PDX argues that it is insulated from liability under Section 230 of. 
the Communications Decency Act ("CDN'). The Court of Appeal decision 
correctly stated that the claims in this case do not arise from PDX's role as 
a software provider enabling Safeway to access the monograph. (Op. at 
12.) The claims were bronght because PDX "intentionally modified its 
software to allow Safeway to distribute abbreviated drug monographs .. ," 
which is conduct that is not immnnized by the CDA. (Jd.) 
PDX inaptly analogizes its role to that of an internet website that 
publishes content provided by others. But as the Court of Appeal explained, 
PDX's conduct in contracting with Safeway to distribute monographs that 
omitted important drug warnings takes this case out of the purview of 
Section 230. '''One need look no further than the face of the statute to see 
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why. The CDA only immunizes 'information provided by another 
infonnation content provider.' (47 U.S.C. § 230 (c )(1).)" (Op. at 12.) 
In addition to the reasons stated in the Court of Appeal decision, 
Section 230 does not apply because Mrs. Hardin was not involved in any 
way with obtaining information online. (Op. at 12.) As the Conrt of Appeal 
noted, and as continues to be true, none ofthe cases upon whichPDX relied 
or that PDX cited applied the CDA to a case such as the present one. (Op. 
at 12.) 
This is a case in which a recipient had no interaction with or 
knowledge of any "interactive computer service." If PDX' s view were 
adopted, the seller of a physical product that used an "interactive computer 
service" to create the paper label could avoid the traditional seller's product 
liability for failure to warn, or a publisher could download defamatory 
information for a website, print it in a newspaper and deliver it to 
newsstands - all without a traditional publisher's liability for defamatory 
content. No case supports such an interpretation. In the information age, 
almost all commerce can be traced back to one or more transactions over 
the Internet. For that reason, to s11"etch the CDA to immunize PDX's 
conduct in this case would lead to unintended and virtually limitless 
immunity from tort liability. 
CONCLUSION 
PDX has provided no grounds for review by this court of the 
decision affirming the den:ial ofPDX's anti-SLAPP motion to strike. 
Review would be unwarranted and premature. Review at this time would 
require this Court to make determinations of controlling tactual issues at 
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the pleading stage. Moreover, PDX mischaracterizes the record and makes 
factual misstatements in seeking protection nuder the First Amendment. 
The decision ofthe Court of Appeal does not, as PDX suggests, burden 
First Amendment rights or permit liability for truthful summaries of public 
records. There is no First Amendment immunity for harm caused by 
omitting neeessary drug wamings. 
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